SABCS 2024 – Lilly's PI3Kα push is no longer mutation-specific
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
Relay passes on the lirafugratinib baton
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
ESMO 2024 – Scorpion joins Relay in the alpha club
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
An alpha turnaround for Relay
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
Cell cycle niche seeks clinical validation
Several companies have followed Pfizer into CDK2 inhibitor development, but the jury is out on this field’s promise.
Triple meeting 2023 – Relay shifts to a tumour-agnostic plan
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.
